Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
0.4096
-0.0127 (-3.01%)
At close: Feb 18, 2026, 4:00 PM EST
0.4113
+0.0017 (0.42%)
Pre-market: Feb 19, 2026, 8:35 AM EST
Outlook Therapeutics Stock Forecast
OTLK's stock price has decreased by -78.1% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Outlook Therapeutics stock have a consensus rating of "Buy" and an average price target of $3.83, which forecasts a 835.06% increase in the stock price over the next year. The lowest target is $0.50 and the highest is $10.
Price Target: $3.83 (+835.06%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $0.5 | Hold | Reiterates | $0.5 | +22.07% | Feb 18, 2026 |
| Chardan Capital | Chardan Capital | Hold Maintains $1 | Hold | Maintains | $1 | +144.14% | Feb 18, 2026 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 → $1 | Hold | Maintains | $3 → $1 | +144.14% | Jan 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $0.5 | Hold | Maintains | $1 → $0.5 | +22.07% | Jan 2, 2026 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $8 → $10 | Strong Buy | Maintains | $8 → $10 | +2,341.41% | Dec 22, 2025 |
Financial Forecast
Revenue This Year
21.56M
from 1.41M
Increased by 1,425.11%
Revenue Next Year
49.56M
from 21.56M
Increased by 129.89%
EPS This Year
-0.63
from -1.79
EPS Next Year
-0.46
from -0.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 48.3M | 139.3M | |||
| Avg | 21.6M | 49.6M | |||
| Low | 8.4M | 17.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3,318.6% | 546.1% | |||
| Avg | 1,425.1% | 129.9% | |||
| Low | 496.2% | -20.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.29 | -0.20 | |||
| Avg | -0.63 | -0.46 | |||
| Low | -0.97 | -0.82 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.